Great Lakes Advisors LLC Has $4.96 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Great Lakes Advisors LLC lowered its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 33.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,435 shares of the company’s stock after selling 40,731 shares during the quarter. Great Lakes Advisors LLC owned 0.16% of Prestige Consumer Healthcare worth $4,957,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its stake in Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares in the last quarter. First Horizon Corp bought a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $32,000. Elevation Point Wealth Partners LLC acquired a new position in Prestige Consumer Healthcare during the 2nd quarter worth approximately $46,000. Geneos Wealth Management Inc. raised its stake in Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares during the period. Finally, First Horizon Advisors Inc. boosted its holdings in Prestige Consumer Healthcare by 294.1% in the second quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after acquiring an additional 447 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PBH has been the subject of several recent research reports. Oppenheimer decreased their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Jefferies Financial Group restated a “hold” rating and issued a $66.00 target price on shares of Prestige Consumer Healthcare in a report on Friday. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group dropped their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.50.

Prestige Consumer Healthcare Trading Up 1.0%

Shares of PBH stock opened at $64.54 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 2.01 and a beta of 0.40. Prestige Consumer Healthcare Inc. has a 52-week low of $57.25 and a 52-week high of $90.04. The company has a 50-day simple moving average of $62.52 and a two-hundred day simple moving average of $64.39.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The company’s revenue was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at $2,539,740. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).